At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trial
L. Campeau; D.B. Hunninghake; J.A. Herd; G. Knatterud; J.L. Probstfield; S. Yusuf; J.S. Forrester; I. Goldenberg; B. Hoogwerf; C. White; M. Domanski; J. Davignon; NIH Post-CABG Clinical Trial Investigators
- 作者L. Campeau; D.B. Hunninghake; J.A. Herd; G. Knatterud; J.L. Probstfield; S. Yusuf; J.S. Forrester; I. Goldenberg; B. Hoogwerf; C. White; M. Domanski; J. Davignon; NIH Post-CABG Clinical Trial Investigators
- 卷第109卷
- 文件大小150.78KB
- 发表时间1994
- DOI10.1016/0021-9150(94)93625-0
- 页码153-153